Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company ...
Zacks Investment Research on MSN
Cytokinetics (CYTK) expected to beat earnings estimates: Should you buy?
Cytokinetics (CYTK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Zacks Investment Research on MSN
Vanda Pharmaceuticals (VNDA) reports Q3 loss, tops revenue estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago. These ...
Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter royalty revenue growth of 51% year over year to approximately $70 ...
Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Merck & Company, with a price target of $170.00. The company’s shares closed yesterday at $141.82. Divan covers ...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September ...
The new Kidney Care National Plan from the US Department of Health and Human Services focuses on preventing kidney failure, ...
Get the detailed balance sheet for Travere Therapeutics, Inc. (TVTX). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue.
A San Antonio singer accused of possessing child pornography is now also the subject of a video that allegedly shows a man ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results